You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 3, 2025

Details for Patent: 5,994,409


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,994,409
Title: Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
Abstract:The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.
Inventor(s): Stogniew; Martin (Blue Bell, PA), Alberts; David S. (Tucson, AZ), Kaplan; Edward H. (Skokie, IL)
Assignee: U.S. Bioscience, Inc. (West Conshohocken, PA) The Arizona Board of Regents on behalf of the University of Arizona (Tuscon, AZ)
Application Number:08/987,550
Patent Claim Types:
see list of patent claims
Use; Delivery;
Patent landscape, scope, and claims:

United States Patent 5,994,409: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 5,994,409, titled "Methods for treatment of neuro- and nephro-disorders and therapeutic toxicities using aminothiol compounds," is a significant patent in the field of medical treatments, particularly focusing on the use of aminothiol compounds. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Background of the Patent

The patent, issued to various inventors, pertains to methods for treating neuro- and nephro-disorders, as well as therapeutic toxicities, using aminothiol compounds. Aminothiols, such as amifostine, have been shown to have protective effects against certain types of damage caused by chemotherapy and radiation therapy[4].

Scope of the Patent

The scope of the patent is broad and encompasses several key areas:

Treatment of Neuro-Disorders

The patent includes methods for treating neuro-disorders, which can arise from various therapeutic interventions, including chemotherapy and radiation therapy. These methods involve administering aminothiol compounds to mitigate neurotoxicity[4].

Treatment of Nephro-Disorders

It also covers the treatment of nephro-disorders, such as renal insufficiency and kidney failure, which can be side effects of certain therapeutic treatments. The use of aminothiol compounds is aimed at reducing the nephrotoxic effects of these treatments[4].

Therapeutic Toxicities

The patent addresses the treatment of therapeutic toxicities, including those associated with chemotherapy agents like cisplatin, carboplatin, and doxorubicin. Aminothiol compounds are administered to protect against these toxicities[4].

Claims of the Patent

The patent includes several claims that define the scope of the invention:

Independent Claims

  • The patent claims methods for treating neuro- and nephro-disorders by administering specific aminothiol compounds.
  • It also claims methods for reducing therapeutic toxicities associated with chemotherapy and radiation therapy using these compounds[4].

Dependent Claims

  • These claims further specify the types of aminothiol compounds used, the dosage forms, and the administration routes.
  • They also detail the specific conditions treated, such as neurotoxicity, renal insufficiency, and cancer-related toxicities[4].

Patent Landscape

Related Patents and Applications

The patent landscape around US 5,994,409 includes other patents and applications related to the use of aminothiol compounds in medical treatments. For instance, other patents may cover different applications of aminothiols or variations in the compounds used[4].

International Patent Family

The patent is part of an international patent family, with corresponding applications filed in other countries. This is evident from the global dossier services provided by the USPTO, which allow users to see the patent family for a specific application across participating IP offices[1].

Prior Art and Citations

The patent cites prior art related to the use of aminothiol compounds in medical treatments. The Common Citation Document (CCD) application, which consolidates prior art cited by participating IP offices, would be useful in understanding the prior art landscape for this patent[1].

Expiration and Freedom to Operate (FTO)

The patent has expired, which means that the methods and compounds described are now in the public domain. This expiration allows other entities to use the disclosed methods and compounds without infringing on the original patent[5].

Economic and Research Implications

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset provides detailed information on claims from U.S. patents, including those related to medical treatments. This dataset can be used to analyze trends and scope measurements of patents like US 5,994,409[3].

Economic Impact

The expiration of this patent can have significant economic implications, as it opens up the market for generic versions of the treatments described. This can lead to increased competition and potentially lower costs for patients.

Practical Applications and Industry Impact

Clinical Use

The methods described in the patent have been clinically used to protect patients from the toxic effects of chemotherapy and radiation therapy. The use of aminothiol compounds like amifostine has been a standard practice in certain medical protocols[4].

Pharmaceutical Industry

The pharmaceutical industry has benefited from this patent by developing and marketing products based on the disclosed methods. With the patent's expiration, other pharmaceutical companies can now develop and market similar products, potentially increasing market competition.

Key Takeaways

  • Scope and Claims: The patent covers methods for treating neuro- and nephro-disorders and therapeutic toxicities using aminothiol compounds.
  • Patent Landscape: The patent is part of an international patent family and has expired, allowing for public use of the disclosed methods.
  • Economic Implications: The expiration of the patent can lead to increased competition and lower costs for patients.
  • Practical Applications: The methods have been clinically used to protect patients from toxic effects of chemotherapy and radiation therapy.

FAQs

Q: What is the main focus of United States Patent 5,994,409?

A: The main focus is on methods for treating neuro- and nephro-disorders and therapeutic toxicities using aminothiol compounds.

Q: What are the key claims of the patent?

A: The patent claims methods for treating neuro- and nephro-disorders and reducing therapeutic toxicities associated with chemotherapy and radiation therapy using aminothiol compounds.

Q: Has the patent expired?

A: Yes, the patent has expired, which means the methods and compounds described are now in the public domain.

Q: What is the economic impact of the patent's expiration?

A: The expiration can lead to increased competition and potentially lower costs for patients as other entities can now use the disclosed methods and compounds.

Q: How can one search for similar patents or related information?

A: One can use resources like the USPTO's Patent Public Search tool, Global Dossier, and international patent databases to search for similar patents and related information[1].

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. Google Patents - US5994409A: https://patents.google.com/patent/US5994409A/de
  3. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. Google Patents - US5994409A: https://patents.google.com/patent/US5994409A/en
  5. Drug Patent Watch - Patent 5,994,409: https://www.drugpatentwatch.com/p/patent-claims/5994409

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 5,994,409

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

International Family Members for US Patent 5,994,409

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Australia 1718499 ⤷  Try for Free
Australia 739068 ⤷  Try for Free
Austria 326956 ⤷  Try for Free
Brazil 9813524 ⤷  Try for Free
Canada 2313089 ⤷  Try for Free
China 1161113 ⤷  Try for Free
China 1283994 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 7 of 7 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.